T
THC Biomed Intl Ltd
CNSX:THC
THC Biomed Intl Ltd
CNSX:THC
Price:
0.02
CAD
Market Closed
Market Cap:
CA$3.3m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
T
|
THC Biomed Intl Ltd
CNSX:THC
|
CA |
|
T
|
Tureks Turunc Madencilik Ic ve Dis Ticaret AS
IST:MARBL.E
|
TR |
|
F
|
Forgent Power Solutions, Inc
NYSE:FPS
|
US |
|
L
|
Lavras Gold Corp
XTSX:LGC
|
CA |
|
O
|
OVB Holding AG
SWB:O4B
|
DE |
|
Group Eleven Resources Corp
XTSX:ZNG
|
CA |
|
V
|
Vibrant Global Capital Ltd
BSE:538732
|
IN |
|
Black Bear Minerals Ltd
OTC:BKBMF
|
AU |
|
G
|
Glory View Technology Co Ltd
SZSE:301396
|
CN |
|
F
|
Filament Health Corp
NEO:FH
|
CA |
|
FST Ltd
NASDAQ:KBSX
|
SG |
|
Panatlantica SA
BOVESPA:PATI4
|
BR |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
HK |
|
Glittek Granites Ltd
BSE:513528
|
IN |
|
M
|
Meren Energy Inc
F:AFZ0
|
CA |
|
Isetan Mitsukoshi Holdings Ltd
OTC:IMHDF
|
JP |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of THC.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
THC
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
THC Competitors Multiples
THC Biomed Intl Ltd Competitors
THC Biomed Intl Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
T
|
THC Biomed Intl Ltd
CNSX:THC
|
3.4m CAD | 1.2 | -0.9 | -2.7 | -1.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
900.7B USD | 13.8 | 43.6 | 29.4 | 31.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
581B USD | 6.2 | 21.7 | 15.1 | 18.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236B GBP | 5.3 | 30.3 | 16.8 | 23.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.4 | 11.5 | 13 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
304.8B USD | 4.7 | 16.7 | 10.3 | 12.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
232.5B CHF | 5.2 | 20.8 | 12.8 | 16.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.2B USD | 2.5 | 20.1 | 7.7 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.2B USD | 2.5 | 16.9 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
